humanitarian
Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Date of authorisation: 29/03/2017, Revision: 16, Status: Authorised
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
6 reports · 2 sources
EMA What Is NewHuman medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 46, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Nordimet, methotrexate, Date of authorisation: 18/08/2016, Revision: 26, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Jylamvo, methotrexate, Date of authorisation: 29/03/2017, Revision: 16, Status: Authorised4 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources